摘要
采用随机单盲对照方法,观察比较血脂康与美百乐镇的调脂疗效。44例高脂血症患者随机分为血脂康组和美百乐镇组各22例,疗程12周。结果显示:12周末血脂康组和美百乐镇组比较,总胆固醇、低密度脂蛋白胆固醇、载脂蛋白B分别下降26.59%和18.92%、33.32%和24.24%、18.42%和8.89%,各自与治疗前相比及同期两组间比较均存在显著差异(P<0.01~0.001),血脂康组中高密度脂蛋白胆固醇升高13.9%(P<0.01),提示血脂康是国产高效的新一代调脂药。
The study was conducted in 44 patients with essential hyperlipidemia.They were randomly and equally divided to receive Xuezhikang and Mevalotin(10 mg daily)for a period of 12 weeks.At the end of the study,the data in decreasing TC,LDL C,ApoB and in increasing HLD C suggested that Xuezhikang is superior to Mevalotin.
出处
《中国新药杂志》
CAS
CSCD
1997年第4期265-268,共4页
Chinese Journal of New Drugs
关键词
血脂康
美百乐镇
高脂血症
血脂
载脂蛋白
Xuezhikang
Mevalotin:Hyperlipidemia
Plasma lipids
Apolipoprotein